2021 annual financial guidance
Company: Core Scientific
The claim, verbatim
Core Scientific expected 2021 revenue of $515-545 million, net income of $50-60 million, and adjusted EBITDA of $225-235 million.
Source (primary)
Core Scientific, Inc. — Entry #1842: Adversary case 22-03345 (RECAP (purchased via PACER), court_filing)
View cached copy (2026-09-26)Live source ↗
Quote: “We expect 2021 revenue to be $515 million to $545 million, net income of $50 million to $60 million and adjusted EBITDA of $225 million to $235 million.”
How we checked this
Checked on September 28, 2026. The cited source supports every part of this claim.
The complaint quotes Core Scientific's March 7, 2022 press release giving this preliminary 2021 guidance.
Confirmed in the source:
- Core Scientific expected 2021 revenue of $515 million to $545 million
- Core Scientific expected 2021 net income of $50 million to $60 million
- Core Scientific expected 2021 adjusted EBITDA of $225 million to $235 million
What we did: Read our cached copy of RECAP (purchased via PACER) (https://storage.courtlistener.com/recap/gov.uscourts.txsb.460090/gov.uscourts.txsb.460090.1842.0.pdf) in full (60,424 characters, retrieved September 26, 2026) and checked each assertion in the claim against it.
Additional evidence
confirms Core Scientific, Inc. — Entry #1842: Adversary case 22-03345
Quote: “We expect 2021 revenue to be $515 million to $545 million, net income of $50 million to $60 million and adjusted EBITDA of $225 million to $235 million.”